Patents Assigned to Universite de Montpellier
  • Publication number: 20170067105
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Patent number: 9556489
    Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: January 31, 2017
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jamal Tazi, Julian Venables, Aude Garcel, Noëlle Campos, Florence Mahuteau-Betzer, Romain Najman, Didier Scherrer
  • Publication number: 20170013829
    Abstract: An adjuvant composition that contains (a) one or more anionic surfactant compounds, (b) one or more one or more fatty acid alkyl ester compounds, and (c) one or more salts is useful as a component of pesticide compositions.
    Type: Application
    Filed: July 14, 2016
    Publication date: January 19, 2017
    Applicants: Rhodia Operations, Centre National de la Recherche Scientifique, Université de Montpellier
    Inventors: Clara VERNAY, Rajesh GOYAL, Laurence RAMOS, Christian LIGOURE, Jean-Christophe CASTAING
  • Patent number: 9504732
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 29, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • Patent number: 9481863
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: November 1, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER 1
    Inventor: Samir Hamamah
  • Publication number: 20160279097
    Abstract: The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.
    Type: Application
    Filed: October 15, 2014
    Publication date: September 29, 2016
    Applicants: Centre National de la Recherche Scientifique, Universite de Montpellier, University of Parma, Ecole Nationale Superieure de Chimie
    Inventors: Gerard Cros, Alan Crozier, Margherita Dall'asta, Daniele Del Rio, Richard Magous, Catherine Oiry
  • Patent number: 9453259
    Abstract: Disclosed herein are methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, provided herein is a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from the patient wherein the genes are FGFBP1, MUC20, TMPRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: September 27, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Delphine Haouzi
  • Patent number: 9409988
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 9, 2016
    Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'Aurelle
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Publication number: 20160201128
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 14, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Patent number: 9389285
    Abstract: A micromagnetometry system for detecting the presence of very small quantities of magnetic particles comprises a first magnetic hybrid AMR/PHR multiring sensor using a Wheastone bridge electrical configuration, a first current source, a first voltage measurement device, a set of at least one magnetic particles deposited on the first magnetic sensor and a processing unit for detecting from a set of different measured differential voltages a magnetic flux shift representative of the presence of a least one deposited magnetic particle. The micromagnetometry system comprises means for creating a magnetic excitation field HAC to make produce by each motionless magnetic particle a stray magnetic field oscillating along the time at a constant frequency ? ranging from 10 Hz to 3 KHz.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: July 12, 2016
    Assignees: UNIVERSITÉ DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Férial Terki, Azzedine Bousseksou, Quang Hung Tran, Souleyman Kamara, CheolGi Kim, Kun Woo Kim, Philippe Gandit
  • Publication number: 20160185856
    Abstract: The present invention relates to anti-claudin 1 antibodies and their uses thereof. In particular, the present invention relates to an anti-Claudin 1 (CLDN1) antibody comprising n heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO:6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region.
    Type: Application
    Filed: July 22, 2014
    Publication date: June 30, 2016
    Applicants: INSERM(Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: Marguerite DEL RIO, Nadia VEZZIO-VIE
  • Publication number: 20160159790
    Abstract: This invention concerns pyrroloquinoline derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in schizophrenia, anxiety, depression, maniac depression, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, panic attacks, attention deficit hyperactivity disorder, attention deficit disorder, Parkinson's disease, Huntington's disease, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, obesity and type-2 diabetes, functional bowel disorder, Irritable Bowel Syndrome. The compounds have the general formula (XIV), wherein the symbols have the meanings given in the description.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 9, 2016
    Applicants: Uniwersytet Jagiellonski, Instytut Farmakologii Polskiej Akademii Nauk, Centre National De La Recherche Scientifique, Universite de Montpellier
    Inventors: Pawel ZAJDEL, Katarzyna GRYCHOWSKA, Maciej PAWLOWSKI, Anna PARTYKA, Anna WESOLOWSKA, Andrzej J. BOJARSKI, Piotr POPIK, Tomasz KOS, Grzegorz SATALA, Frederic LAMATY, Evelina COLACINO, Jean MARTINEZ, Giles SUBRA, Xavier BANTREIL
  • Patent number: 9358324
    Abstract: The present invention relates to a hydrophobic polymer used in particular to produce and/or coat medical devices, in particular implantable medical devices, that are visible in magnetic resonance imaging, characterized in that it comprises at least one monomer unit on which is grafted a chelating ligand of a paramagnetic ion complexed with such a paramagnetic ion, said monomer unit having at least one carbonyl group, said monomer unit comprising, prior to grafting, at least one hydrogen atom in the ? position of said at least one carbonyl group, and said grafting of the chelating ligand taking place in the area of said at least one hydrogen atom in the ? position of said at least one carbonyl group.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: June 7, 2016
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 2, UNIVERSITE DE MONTPELLIER 1, CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES
    Inventors: Sebastien Blanquer, Jean Coudane, Renaud De Tayrac, Xavier Garric, Vincent Letouzey, Olivier Guillaume
  • Publication number: 20160151348
    Abstract: Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n? is 1 or 2, R? is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.
    Type: Application
    Filed: July 4, 2014
    Publication date: June 2, 2016
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Didier SCHERRER, Noëlie CAMPOS, Aude GARCEL
  • Publication number: 20160096865
    Abstract: The invention relates to novel peptide-silane “hybrid block” molecules, to the synthesis thereof and to the use of same for producing novel peptide-silica hybrid materials that can be used in various applications.
    Type: Application
    Filed: June 24, 2013
    Publication date: April 7, 2016
    Applicant: Universite de Montpellier I
    Inventors: Jean MARTINEZ, Gilles SUBRA, Ahmad MEHDI, Said JEBORS, Christine ENJALBAL, Luc BRUNEL, Francois FAJULA
  • Patent number: 9249337
    Abstract: The invention relates to processes for coating a surface with a crosslinked polyelectrolytes multilayer film incorporating a protein, preferably a growth factor type protein. The invention also relates to crosslinked polyelectrolytes multilayer films obtained by this process, and a coated surface obtained therefrom.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 2, 2016
    Assignees: INSTITUT POLYTECHNIQUE DE GRENOBLE, UNIVERSITE DE MONTPELLIER
    Inventors: Catherine Picart, Thomas Crouzier
  • Patent number: 9249228
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 2, 2016
    Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • Publication number: 20150307887
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Application
    Filed: July 8, 2015
    Publication date: October 29, 2015
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCEINCES ET TECHNIQUES
    Inventor: Jean VALMIER
  • Patent number: 9169316
    Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: October 27, 2015
    Assignees: Centre National de la Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val d'Aurelle, Institut Paoli Calmettes
    Inventors: Daniel Baty, Ghislaine Behar, Martine Chartier, André Pelegrin, Jean-luc Teillaud, Isabelle Teulon
  • Publication number: 20150297573
    Abstract: The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting ?-cell survival and function in a number of applications.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 22, 2015
    Applicants: INSERM (Institut National De La Santé Et De La Recherche Médicale), Université De Montpellier
    Inventors: Stéphane Dalle, Jean-Francois Tanti, Anne Wojtusciszyn, Elodie Varin